No Data
No Data
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Announces Target Price $25
Haitong Int'l: maintains a "outperform" rating on Zai Lab (09688) with a target price lowered to HKD 65.76.
According to Haitong, driven by the sales of Agamode and three other potential blockbuster products, the company is expected to achieve a revenue growth of around 50% CAGR during 2023-2028.
Zai Lab Rewards Employees With Equity Incentive
Zai Lab (09688.HK) granted restricted share units.
On August 13th, Gelunhui reported that Zai Lab (09688.HK) announced that on August 12th, 2024 (US Eastern Time), the company granted a total of 7 restricted share units to 7 grant recipients under the 2024 stock-based incentive plan, involving a total of 7000 American depositary shares.
Buy Rating Affirmed for Zai Lab on Strong Financials and Promising Pipeline Developments
Major Bank Rating | Bank of America Merrill Lynch: Raises Zai Lab's Target Price to HKD 19.38, Maintains "Buy" Rating.
Bank of America Securities' report states that Zai Lab's commercial performance in the second quarter was stable. Due to its solid sales performance and on-track R&D progress, the target price was raised from HKD 16.28 to HKD 19.38, maintaining a 'buy' rating. The report mentions the strong growth of its medications VYVGART/NUZYRA/QINLOCK after their inclusion in the National Medical Insurance Drug List, leading to an upward revision of revenue forecasts after 2024.
No Data